{
    "clinical_study": {
        "@rank": "13335", 
        "acronym": "HELICON", 
        "brief_summary": {
            "textblock": "To characterize and estimate the size of different populations with a history of acute\n      coronary syndrome in Sweden. To assess the burden of illness (co-morbidities, mortality\n      rates healthcare resource utilization and atherothrombotic events) among patients with a\n      history of myocardial infarction (MI) 1-3 years ago and additional risk factors for\n      atherothrombosis."
        }, 
        "brief_title": "A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients hospitalised for ACS between 01.07.2006 and 31.06.2011.\n\n        Exclusion Criteria:\n\n        - Not applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patient with acute coronary syndrome with a history of MI 1-3 years ago."
            }
        }, 
        "enrollment": {
            "#text": "100000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984307", 
            "org_study_id": "ME-CV-1302"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute coronary syndrome", 
            "Myocardial infarction", 
            "retrospective", 
            "cohort study", 
            "Healthcare resources utilization"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Linkoping", 
                    "country": "Sweden"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis", 
        "overall_official": {
            "affiliation": "Department of Cardiology, Link\u00f6ping University Hospital, S-581 85 Link\u00f6ping, Sweden", 
            "last_name": "Magnus Janzon, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Sweden: The Swedish National Board of Health and Welfare\"", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "1. Death (all cause and CVD death) 2. CVD event (MI or Stroke) 3. Health care resource use and costs.", 
                "measure": "Description of study population in terms of death, cardiovascular disease events and health care resource utilization", 
                "safety_issue": "No", 
                "time_frame": "Follow up period 1-7 years"
            }, 
            {
                "description": "1. Describe patients' demographics and clinical characteristics 2. Assess rate of CV event (MI and stroke), CV mortality and all cause mortality 3. Assess rate of CV events (MI and stroke), CV mortality and all cause mortality in patients having at least 24 months and 36 months without MI, respectively 4. Assess the impact of additional atherothrombotic risk factors 5. Describe treatment patterns 6. Evaluate healthcare resource use and costs 7. Assess predictors of new CV events (MI and stroke), CV mortality and all cause mortality", 
                "measure": "Assessment of the burden of illness among high risk patients with a history of MI", 
                "safety_issue": "No", 
                "time_frame": "Follow up period 1-7 years"
            }, 
            {
                "description": "1. Describe patients' demographics and clinical characteristics 2. Assess rate of CV event (MI and stroke), CV mortality and all cause mortality 3. Assess rate of CV events (MI and stroke), CV mortality and all cause mortality in patients having at least 24 months and 36 months without MI, respectively 4. Assess the impact of additional atherothrombotic risk factors 5. Describe treatment patterns 6. Evaluate healthcare resource use and costs 7. Assess predictors of new CV events (MI and stroke), CV mortality and all cause mortality", 
                "measure": "Assessment of the mortality rates among high risk patients with a history of MI", 
                "safety_issue": "No", 
                "time_frame": "Follow up period 1-7 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "1. Assess rate of other CVD events (including heart failure, atrial fibrillation, angina pectoris) 2. Assess prevalence and rate of (major) organ specific bleedings (recorded diagnose in hospital) 3. Describe patients/proportions of patients with increased bleeding risk (history of previous bleedings, age, anti-thrombotic treatment etc) 4. Assess the prevalence of major co-morbidities in this population: (e.g. bradycardia, insertion of pacemaker, acute liver and renal failure) 5. To describe the death rate for the most common cause of deaths in the study population relative to the standardized death rate in the Swedish population and calculate the standardised mortality ratio", 
            "measure": "Description of the high risk patient population in terms of CVD events, bleedings and co-morbidities.", 
            "safety_issue": "No", 
            "time_frame": "Follow up period 1-7 years"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}